Acelarin (fosgemcitabine palabenamide) / NuCana  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Acelarin (fosgemcitabine palabenamide) / NuCana
ACELARATE, NCT03610100 / 2014-004653-14: Acelarin First Line Randomised Pancreatic Study

Suspended
3
328
Europe
Acelarin, NUC-1031, Gemcitabine, Gemzar
The Clatterbridge Cancer Centre NHS Foundation Trust, Cancer Research UK, University of Liverpool
Pancreatic Acinar Carcinoma, Pancreatic Neoplasms
09/20
12/22
NuTide:121, NCT04163900 / 2019-001025-28: Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer

Terminated
3
773
Europe, Canada, US, RoW
NUC-1031, fosgemcitabine palabenamide, Gemcitabine, Difluorodeoxycytidine, Gemzar, Cisplatin, CDDP
NuCana plc
Biliary Tract Cancer
03/22
04/22

Download Options